News >

UGN-102 Active in Non-Muscle Invasive Bladder Cancer

Jason M. Broderick @jasoncology
Published: Friday, Apr 03, 2020

Mark P. Schoenberg, MD

Mark P. Schoenberg, MD

UGN-102 (mitomycin) for intravesical solution induced a 65% complete response (CR) rate in patients with low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC), according to interim data from the phase IIb OPTIMA II trial published in The Journal of Urology.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication